Norwegian drugmaker Vaccibody has finalized a deal with Genentech for the development of personalized cancer vaccines.

Vaccibody’s investigational vaccine candidate, VB10.NEO, is currently undergoing early-stage trials in the U.S. and Europe. The candidate is intended for use as a therapeutic in patients with locally advanced or metastatic solid tumors.

The personalized medicine approach will enable each patient to receive a unique vaccine to generate an immune response.

Under the agreement, Vaccibody will receive $200 million in initial and near-term payments, with the potential for $515 million in milestone payments and additional royalties.